Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
